Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells

Mostrar otras versiones (1)

The nitrogen-containing bisphosphonates (N-BP) zoledronic acid (ZOL) inhibits osteoclast-mediated bone resorption, and it is used to prevent skeletal complications from bone metastases. ZOL has also demonstrated anticancer activities in preclinical models and, recently, in cancer patients, highlight...

Descripción completa

Detalles Bibliográficos
Autores principales: Milone, M R, Pucci, B, Bruzzese, F, Carbone, C, Piro, G, Costantini, S, Capone, F, Leone, A, Di Gennaro, E, Caraglia, M, Budillon, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674372/
https://www.ncbi.nlm.nih.gov/pubmed/23703386
http://dx.doi.org/10.1038/cddis.2013.165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674372/
https://www.ncbi.nlm.nih.gov/pubmed/23703386
http://dx.doi.org/10.1038/cddis.2013.165

Ejemplares similares